| 孙婷,张希远,赵鹏,等.FGFR3、FGF2在弥漫大 B细胞淋巴瘤中的表达及临床相关性分析[J].安徽医药,2025,29(8):1578-1583. |
| FGFR3、FGF2在弥漫大 B细胞淋巴瘤中的表达及临床相关性分析 |
| Expression and clinical correlation analysis of FGFR3 and FGF2 in diffuse large B-cell lymphoma |
| |
| DOI：10.3969/j.issn.1009-6469.2025.08.018 |
| 中文关键词: 淋巴瘤，大 B细胞，弥漫性 成纤维生长因子受体 -3 成纤维生长因子 -2 病理状态，体征和症状 预后 |
| 英文关键词: Lymphoma, large B-cell, diffuse Fibroblast growth factor receptor 3 Fibroblast growth factor 2 Pathological condi-tions, signs and symptoms Prognosis |
| 基金项目: |
|
| 摘要点击次数: 736 |
| 全文下载次数: 235 |
| 中文摘要: |
| 目的探讨弥漫大 B细胞淋巴瘤( DLBCL)中成纤维生长因子受体 -3(FGFR3)、成纤维生长因子 -2(FGF2)的表达与临床病理特征及预后的关系。方法选取青岛市中心医院 2014年 1月至 2022年 8月初诊的 60例 DLBCL病人为研究对象，另取 20例反应性增生性淋巴结作为阴性对照。采用免疫组织化学染色检测 60例 DLBCL组织中 FGFR3、FGF2的表达水平。使用 χ2检验分析 FGFR3、FGF2的表达与 DLBCL病人临床病理特征的相关性， Kaplan-Meier法进行生存分析，并采用 Cox回归模型评估与 DLBCL病人预后相关的危险因素。结果与反应性增生性淋巴结相比， FGFR3、FGF2在 DLBCL中呈高表达［71.7%(43/60)比 15.0%(3/20)、60%(36/60)比 10%(2/20)，P<0.05］； FGFR3的表达水平与病人的 Lugano分期、 B症状、 Hans分型及结外器官浸润数量有关( P<0.05)FGF2表达水平与病人 Lugano分期、有无侵犯骨髓、 Hans分型有关( P<0.05)； Kaplan-Meier生存分析显示， FGFR3高表达的病人，与 FGFR3低表达的病人相比，无进展生存期( PFS)和总生存期( OS)显著缩短( P<0.05)。此外， FGF2高表达病人的 PFS也明显较短于 FGF2低表达病人(P<0.05)。而且，在 FGF2和 FGFR3均高表达的 DLBCL病人中，其 PFS和 OS都较低表达组更短( P<0.05)。 Cox多因素分析结果显示，国际预后指数( IPI)评分［HR=2.80，95%CI:(1.08，7.25)］、有无大包块［HR=2.98，95%CI:(1.04，8.51)］以及 FGFR3表达水平［HR=3.21，95%CI:(1.24，8.34)］是影响 DLBCL总生存期的独立预后因素(P<0.05)。结论 FGFR3、FGF2在 DLBCL中高表达，且标志着 DLBCL病人预后差。 |
| 英文摘要: |
| Objective To investigate the expression levels of fibroblast growth factor receptor 3 (FGFR3) and fibroblast growth factor2 (FGF2) in diffuse large B-cell lymphoma (DLBCL) and their correlation with clinicopathological features and patient prognosis.Meth. ods This study included DLBCL patients initially diagnosed at Qingdao Central Hospital from January 2014 and August 2022, and 20patients with reactive lymph node hyperplasia as negative controls. Immunohistochemical staining was used to assess FGFR3 andFGF2 expression levels in DLBCL tissues. The relationships between FGFR3/FGF2 expression and clinicopathological features wereanalyzed using the chi-square test. Kaplan-Meier survival analysis and Cox regression model were applied to evaluate prognosis-related risk factors.Results FGFR3 and FGF2 expression levels were significantly higher in DLBCL than in reactive lymph node hyperplasia [71.7% (43/60) vs. 15.0% (3/20) , 60% (36/60) vs. 10% (2/20), P < 0.05]. FGFR3 expression correlated with Lugano stage, B symptoms, Hans classification, and extranodal organ involvement (P < 0.05). FGF2 expression correlated with Lugano stage, bone marrow invasion and Hans classification (P < 0.05). Kaplan-Meier analysis showed that high FGFR3 expression was associated with significantly shorter progression-free survival (PFS) and overall survival (OS) compared to low FGFR3 expression (P < 0.05). Similarly, high FGF2 expres-sion indicated shorter PFS (P < 0.05). Patients with combined high FGF2 and FGFR3 expression had significantly shorter PFS and OS (P < 0.05). Cox multivariate analysis identified international prognostic index (IPI) score [HR=2.80, 95%CI: (1.08, 7.25)], large mass presence [HR=2.98, 95%CI: (1.04, 8.51)], and FGFR3 expression level [HR=3.21, 95%CI: (1.24, 8.34)] as independent prognostic fac-tors (P < 0.05).Conclusion High expression of FGFR3 and FGF2 in DLBCL indicates poor prognosis in DLBCL patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
